Herpes Simplex Virus (HSV) Vaccines Market Size, Share, Growth, Outlook, and Opportunity
Analysis, 2018-2026
Herpes simplex virus (HSV) is known for causing herpes infection. This is majorly found on genitals or
mouth and can also be seen on various body parts. There are two types of herpes simplex virus, type
1 (HSV-1) and type 2 (HSV-2), in which HSV-1 is oral herpes causing sores around lips and mouth
(fever blisters or cold sores), while HSV-2 is genital herpes, wherein sores are found around genitals
and rectum. HSV-1 is very common and extremely contagious infection, and HSV-1 infections
occurring around mouth are known as orolabial, oral-labial, or oral –facial herpes. A very few cases of
genital herpes (infections occur in genital or anal area) are found in HSV-1. Herpes simplex virus
(HSV-2) is most common sexually transmitted virus causing genital herpes (GH) and also highly
contagious infection. HSV-2 infection is long lasting and incurable. There is more risk for patients
suffering from HSV-2 of getting human immunodeficiency virus (HIV) infection. Probability of
reoccurrence of HSV-1 is less frequent than that of HSV-2.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/2845
Factors such as extensive research and development is expected to support global herpes simplex
virus (HSV) vaccines market growth over the forecast period. Leading players in the market such as
GlaxoSmithKline (GSK), Sanofi SA, and others have HSV vaccines in the development phases.
GSK’s vaccine SB208141 completed phase III studies in 2009, which started in 2003. GSK carried
out several other clinical trial studies on the same vaccine, considering various different parameters
and formulations (with or without monophosphoryl lipid adjuvant [MPL]). Sanofi Pasteur has vaccine
HSV529 for HSV-2 is in phase I, whose clinical trial study started in 2015 and completed in 2018.
Moreover, Vical, Inc. has VCL-HB01, whose phase I study started in September 2016, and completed
in December 2018. Furthermore, Genocea Biosciences, Inc. vaccine GEN-003 is in phase II study
where the study started in November 2015 and completed in May 2017. The company also carried
out various trial studies with the same vaccine by using an adjuvant Matrix-M2 (It is human
respiratory syncytial virus, derived from Quillaja saponins, cholesterol, and phosphatidylcholine).
Therefore, robust pipeline is expected to propel global herpes simplex virus (HSV) vaccines market
growth over the forecast period.
Global Herpes Simplex Virus (HSV) Vaccines Market Regional Analysis
Extensive research and development activities in North America are expected to propel herpes
simplex virus (HSV) vaccines market growth in the region during the forecast period. Several
leading companies are focusing towards research and development of herpes simplex virus
(HSV) vaccines for prevention of it. For instance, GEN-003 of Genocea Biosciences, Inc. (based in
the U.S.) has shown acceptable safety profile in phase III clinical trials in 2017, so it could be first
upcoming vaccine available for HSV in the market boosting global herpes simplex virus (HSV)
vaccines market growth.
Report includes chapters which deeply display the following deliverable about industry :
• Herpes Simplex Virus (HSV) Vaccines Market Research Objective and Assumption
• Herpes Simplex Virus (HSV) Vaccines Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Herpes Simplex Virus (HSV) Vaccines Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Herpes Simplex Virus (HSV) Vaccines Market, By Regions
• Herpes Simplex Virus (HSV) Vaccines Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Herpes Simplex Virus (HSV) Vaccines Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Herpes Simplex Virus (HSV) Vaccines Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Herpes Simplex Virus (HSV) Vaccines Market Forecast including Production, Consumption, Import
and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Global Herpes Simplex Virus (HSV) Vaccines Market Key Players
Some of the major players operating in the global herpes simplex virus (HSV) vaccines market
include Sanofi S.A., GlaxoSmithKline Plc., Genocea Biosciences, Inc., Vical, Inc., and others.
Inquire Here Before Purchase:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2845
Global Herpes Simplex Virus (HSV) Vaccines market Taxonomy
By Vaccine:•
•
•
•
GEN-003
VCL-HB01
HSV529
Others
By Indication:• HSV-1 (Oral Herpes)
• HSV-2 (Genital Herpes)
By Region
•
•
•
•
•
•
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]